Skin and Connective Tissue Diseases

445 trials 165 recruiting

Filter these 445 trials by phase, country and sponsor.

Open in Search →

Effect of briquilimab in patients with patches of itching skin because of chronic spontaneous urticaria (CSU) despite treatment with antihis… Ended

2023-505446-25-00 Chronic Spontaneous Urticaria 9 2024-03-20
52 weeks double-blind, double-dummy, randomized placebo-controlled trial to evaluate safety, efficacy and tolerability of remibrutinib in co… Ended

2022-502161-19-00 Chronic Spontaneous Urticaria 5 2024-03-12
Study to measure filgotinib in the blood of children and teenagers with arthritis taking filgotinib-GLPG0634-CL-131 Ended

2023-505844-21-00 juvenile idiopathic arthritis 3 2024-02-14
Efficacy and Safety of Methotrexate versus Placebo in Adults with Atopic Dermatitis Ended

2023-504443-13-00 moderate to severe atopic dermatitis 5 2024-01-29
Determine effectiveness of Anifrolumab In Systemic sclerosis Ended

2023-505976-31-00 Systemic Sclerosis (SSc) presenting with Limited or Dif 5 2023-11-24
A Phase 3, Open-label, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Romosozumab Compared with Bisphosphonates in Chi… Ended

2023-503294-37-00 Osteogenesis Imperfecta 5 2023-11-20
Local tolerance and PK/PD assessment of TAR-0520 gel when applied topically in healthy subjects Ended

2023-504178-39-00 Prevention of anticancer therapy adverse reactions 3 2023-11-09
A study to test whether spesolimab helps people with Generalized Pustular Psoriasis (GPP) who need treatment for repeated flares Ended

2022-502128-38-00 Generalized Pustular Psoriasis 11 2023-10-11
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata (BRAVE-AA-PEDS) Ended

2022-502700-78-00 Alopecia areata (AA) 5 2023-09-01
DUPI REDUCE trial (DUPIlumab dose REDUCtion in patients with controlled atopic Eczema): a multicenter, low-intervention, non-inferiority ran… Ended

2023-504171-24-00 Atopic eczema 6 2023-08-14
Investigation of tissue-resident memory T-cells and disease MEMory in psoriasis during GUSelkumab treatment. The GUSMEM study. Ended

2023-503776-25-00 Psoriasis vulgaris 6 2023-06-19
TEMP-PREVENT Ended

2024-512133-33-00 Pseudoxanthoma Elasticum 5 2023-04-26
An Open-Label Extension Study to Evaluate Long Term Safety and Efficacy of Tildrakizumab in Patients with Psoriatic Arthritis. Ended

2022-501480-41-00 Psoriatic Arthritis 5 2023-04-06
Dupilumab step-down strategy to maintain remission in adult and adolescents patients with atopic dermatitis: a non-inferiority randomized tr… Ended

2022-501179-23-00 atopic dermatitis 6 2023-03-08
An extension study of long-term efficacy, safety and tolerability of remibrutinib in chronic spontaneous urticaria patients who completed pr… Ended

2024-510818-33-00 Chronic Spontaneous Urticaria 5 2023-01-24
The WILLOW LTE study with enpatoran in participants with SCLE, DLE and/or SLE Ended

2024-510871-39-00 Systemic lupus erythematosus (SLE) and cutaneous lupus 4 2022-11-21
A Phase 4, Multi-centre, Randomized, Evaluator-blinded, Active-controlled Study to Determine the Incidence of Squamous Cell Carcinoma and Ev… Ended

2024-514394-22-00 Actinic Keratosis 6 2022-10-24
Optimization of Cyclosporin therapy in atopic dermatitis through multiomic predictive models of treatment response (DermAtOmics) Ended

2022-500677-14-00 Adult, adolescent and paediatric patients with moderate 6 2022-09-28
Study to see how good and safe Tildrakizumab is in children aged 6 to under 18 years of age with skin patches Ended

2023-504447-14-00 Treatment of pediatric subjects with moderate to severe 10 2021-07-29
A phase 2, open label study to evaluate safety and clinical activity of balstilimab in monotherapy in patients with advanced/metastatic non-… Ended

2024-517380-22-00 Advanced basal cell carcinoma not amenable to local the 4 2021-06-18
A clinical trial evaluating the efficacy and safety of the drugs - cyclosporine and methotrexate in children and adolescents with moderate t… Ended

2023-509759-15-00 atopic dermatitis 5 2021-03-15
A long-term study to assess the safety and efficacy of nemolizumab (CD14152) in subjects with prurigo nodularis (PN) Ended

2024-514502-31-00 Prurigo Nodularis 5 2021-01-11
Long-term study to assess the safety and efficacy of Nemolizumab in subjects with Atopic Dermatitis Ended

2024-514404-13-00 Atopic Dermatitis 5 2020-10-01
An exploratory, multicenter, randomized, open-label with blind evaluation, active controlled study to evaluate the safety and efficacy of Ke… Ended

2024-515667-60-00 Actinic keratosis 4 2020-01-14